Cansativa CEO on Medical Cannabis Market Growth

Question 8: Cansativa in 2030

📑 Inhaltsverzeichnis

Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
Frequently Asked Questions
💬 Fragen? Frag den Hanf-Buddy!

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Question 3: Market Entry & Marketplaces

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Benedikt: I don’t believe in a window that closes on a specific date. I believe in entry barriers that rise with market maturity. Anyone entering today must build not a product but a complete, regulatorily licensed infrastructure, plus manufacturer relationships across fifteen countries, a solid quality system, and the trust of thousands of pharmacies. That’s not something you can buy with capital alone—it takes years.

So the market will be decided by 2027 less through new players than through the question of who truly integrates distribution, brands, and systems. Pure marketplaces that only mediate come under pressure because they sit at the thinnest part of the value chain. But whoever controls the entire chain, from import to pharmacy counter, sets the pace. I’m convinced that integrated platforms will shape this market, not storefronts.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Question 2: Reorientation After CanG

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

Benedikt: The strongest reorientation wasn’t a single function but a leap in self-definition. Before the market opening, we were the reliable distributor supplying the market with product. With legalization, we understood that distribution is the ticket to entry, not the destination. Distribution scales the market, brands scale the margin. So we built a powerhouse of proprietary brands—AMICI and N!CE—on top of our supply chain, complemented by exclusive partnerships.

The crucial thing is where these brands come from. From thousands of pharmacy relationships, we know firsthand what the market demands—market insight of this depth no one else possesses. That’s exactly where we developed products tailored to the needs of pharmacies and their patients. With our own inventory management system, we also made the pharmacy genuinely capable in medicinal cannabis for the first time. Operational logistics, B2B distribution, and internationalization weren’t competing priorities but parts of the same architecture. We turned a wholesaler into an integrated platform, and it carries most of our value today.

Question 3: Market Entry & Marketplaces

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Benedikt: I don’t believe in a window that closes on a specific date. I believe in entry barriers that rise with market maturity. Anyone entering today must build not a product but a complete, regulatorily licensed infrastructure, plus manufacturer relationships across fifteen countries, a solid quality system, and the trust of thousands of pharmacies. That’s not something you can buy with capital alone—it takes years.

So the market will be decided by 2027 less through new players than through the question of who truly integrates distribution, brands, and systems. Pure marketplaces that only mediate come under pressure because they sit at the thinnest part of the value chain. But whoever controls the entire chain, from import to pharmacy counter, sets the pace. I’m convinced that integrated platforms will shape this market, not storefronts.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Question 1: Market Share

Since 2024, Cansativa has been a central player in the legalized market. What market shares are we actually talking about, and how do they compare to the three most important competitors?

Benedikt: Let me straighten out a figure first, because it frames the picture. Cansativa is not a child of the 2024 market opening. We’ve been BfArM-licensed since 2017 and were the federal government’s exclusive distribution partner from 2020 to 2024. These eight years of lead time are our foundation today. On that basis, we hold over 28 percent of the German medicinal cannabis market and lead it.

For me, though, this is less about ranking than responsibility. More than 3,000 pharmacies work with us, and over nine out of ten medicinal cannabis-active pharmacies are connected. I deliberately won’t comment on specific competitors‘ figures—I’ll leave that to others. What matters more to me is the structural point: in this business, market share doesn’t come from marketing but from supply capability, licenses, and infrastructure built over years. That’s the distance that can’t be closed in a single quarter.

Question 2: Reorientation After CanG

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

Benedikt: The strongest reorientation wasn’t a single function but a leap in self-definition. Before the market opening, we were the reliable distributor supplying the market with product. With legalization, we understood that distribution is the ticket to entry, not the destination. Distribution scales the market, brands scale the margin. So we built a powerhouse of proprietary brands—AMICI and N!CE—on top of our supply chain, complemented by exclusive partnerships.

The crucial thing is where these brands come from. From thousands of pharmacy relationships, we know firsthand what the market demands—market insight of this depth no one else possesses. That’s exactly where we developed products tailored to the needs of pharmacies and their patients. With our own inventory management system, we also made the pharmacy genuinely capable in medicinal cannabis for the first time. Operational logistics, B2B distribution, and internationalization weren’t competing priorities but parts of the same architecture. We turned a wholesaler into an integrated platform, and it carries most of our value today.

Question 3: Market Entry & Marketplaces

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Benedikt: I don’t believe in a window that closes on a specific date. I believe in entry barriers that rise with market maturity. Anyone entering today must build not a product but a complete, regulatorily licensed infrastructure, plus manufacturer relationships across fifteen countries, a solid quality system, and the trust of thousands of pharmacies. That’s not something you can buy with capital alone—it takes years.

So the market will be decided by 2027 less through new players than through the question of who truly integrates distribution, brands, and systems. Pure marketplaces that only mediate come under pressure because they sit at the thinnest part of the value chain. But whoever controls the entire chain, from import to pharmacy counter, sets the pace. I’m convinced that integrated platforms will shape this market, not storefronts.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

💬 In Conversation

Benedikt Sons, CEO Cansativa GmbH

Benedikt Sons is co-founder and CEO of Cansativa GmbH (Mörfelden-Walldorf), market leader in German medicinal cannabis distribution according to the company. He will present a live podcast at the Mary Jane Berlin.

Question 1: Market Share

Since 2024, Cansativa has been a central player in the legalized market. What market shares are we actually talking about, and how do they compare to the three most important competitors?

Benedikt: Let me straighten out a figure first, because it frames the picture. Cansativa is not a child of the 2024 market opening. We’ve been BfArM-licensed since 2017 and were the federal government’s exclusive distribution partner from 2020 to 2024. These eight years of lead time are our foundation today. On that basis, we hold over 28 percent of the German medicinal cannabis market and lead it.

For me, though, this is less about ranking than responsibility. More than 3,000 pharmacies work with us, and over nine out of ten medicinal cannabis-active pharmacies are connected. I deliberately won’t comment on specific competitors‘ figures—I’ll leave that to others. What matters more to me is the structural point: in this business, market share doesn’t come from marketing but from supply capability, licenses, and infrastructure built over years. That’s the distance that can’t be closed in a single quarter.

Question 2: Reorientation After CanG

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

Benedikt: The strongest reorientation wasn’t a single function but a leap in self-definition. Before the market opening, we were the reliable distributor supplying the market with product. With legalization, we understood that distribution is the ticket to entry, not the destination. Distribution scales the market, brands scale the margin. So we built a powerhouse of proprietary brands—AMICI and N!CE—on top of our supply chain, complemented by exclusive partnerships.

The crucial thing is where these brands come from. From thousands of pharmacy relationships, we know firsthand what the market demands—market insight of this depth no one else possesses. That’s exactly where we developed products tailored to the needs of pharmacies and their patients. With our own inventory management system, we also made the pharmacy genuinely capable in medicinal cannabis for the first time. Operational logistics, B2B distribution, and internationalization weren’t competing priorities but parts of the same architecture. We turned a wholesaler into an integrated platform, and it carries most of our value today.

Question 3: Market Entry & Marketplaces

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Benedikt: I don’t believe in a window that closes on a specific date. I believe in entry barriers that rise with market maturity. Anyone entering today must build not a product but a complete, regulatorily licensed infrastructure, plus manufacturer relationships across fifteen countries, a solid quality system, and the trust of thousands of pharmacies. That’s not something you can buy with capital alone—it takes years.

So the market will be decided by 2027 less through new players than through the question of who truly integrates distribution, brands, and systems. Pure marketplaces that only mediate come under pressure because they sit at the thinnest part of the value chain. But whoever controls the entire chain, from import to pharmacy counter, sets the pace. I’m convinced that integrated platforms will shape this market, not storefronts.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

💬 In Conversation

Benedikt Sons, CEO Cansativa GmbH

Benedikt Sons is co-founder and CEO of Cansativa GmbH (Mörfelden-Walldorf), market leader in German medicinal cannabis distribution according to the company. He will present a live podcast at the Mary Jane Berlin.

Question 1: Market Share

Since 2024, Cansativa has been a central player in the legalized market. What market shares are we actually talking about, and how do they compare to the three most important competitors?

Benedikt: Let me straighten out a figure first, because it frames the picture. Cansativa is not a child of the 2024 market opening. We’ve been BfArM-licensed since 2017 and were the federal government’s exclusive distribution partner from 2020 to 2024. These eight years of lead time are our foundation today. On that basis, we hold over 28 percent of the German medicinal cannabis market and lead it.

For me, though, this is less about ranking than responsibility. More than 3,000 pharmacies work with us, and over nine out of ten medicinal cannabis-active pharmacies are connected. I deliberately won’t comment on specific competitors‘ figures—I’ll leave that to others. What matters more to me is the structural point: in this business, market share doesn’t come from marketing but from supply capability, licenses, and infrastructure built over years. That’s the distance that can’t be closed in a single quarter.

Question 2: Reorientation After CanG

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

Benedikt: The strongest reorientation wasn’t a single function but a leap in self-definition. Before the market opening, we were the reliable distributor supplying the market with product. With legalization, we understood that distribution is the ticket to entry, not the destination. Distribution scales the market, brands scale the margin. So we built a powerhouse of proprietary brands—AMICI and N!CE—on top of our supply chain, complemented by exclusive partnerships.

The crucial thing is where these brands come from. From thousands of pharmacy relationships, we know firsthand what the market demands—market insight of this depth no one else possesses. That’s exactly where we developed products tailored to the needs of pharmacies and their patients. With our own inventory management system, we also made the pharmacy genuinely capable in medicinal cannabis for the first time. Operational logistics, B2B distribution, and internationalization weren’t competing priorities but parts of the same architecture. We turned a wholesaler into an integrated platform, and it carries most of our value today.

Question 3: Market Entry & Marketplaces

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Benedikt: I don’t believe in a window that closes on a specific date. I believe in entry barriers that rise with market maturity. Anyone entering today must build not a product but a complete, regulatorily licensed infrastructure, plus manufacturer relationships across fifteen countries, a solid quality system, and the trust of thousands of pharmacies. That’s not something you can buy with capital alone—it takes years.

So the market will be decided by 2027 less through new players than through the question of who truly integrates distribution, brands, and systems. Pure marketplaces that only mediate come under pressure because they sit at the thinnest part of the value chain. But whoever controls the entire chain, from import to pharmacy counter, sets the pace. I’m convinced that integrated platforms will shape this market, not storefronts.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

💬 In Conversation

Benedikt Sons, CEO Cansativa GmbH

Benedikt Sons is co-founder and CEO of Cansativa GmbH (Mörfelden-Walldorf), market leader in German medicinal cannabis distribution according to the company. He will present a live podcast at the Mary Jane Berlin.

Question 1: Market Share

Since 2024, Cansativa has been a central player in the legalized market. What market shares are we actually talking about, and how do they compare to the three most important competitors?

Benedikt: Let me straighten out a figure first, because it frames the picture. Cansativa is not a child of the 2024 market opening. We’ve been BfArM-licensed since 2017 and were the federal government’s exclusive distribution partner from 2020 to 2024. These eight years of lead time are our foundation today. On that basis, we hold over 28 percent of the German medicinal cannabis market and lead it.

For me, though, this is less about ranking than responsibility. More than 3,000 pharmacies work with us, and over nine out of ten medicinal cannabis-active pharmacies are connected. I deliberately won’t comment on specific competitors‘ figures—I’ll leave that to others. What matters more to me is the structural point: in this business, market share doesn’t come from marketing but from supply capability, licenses, and infrastructure built over years. That’s the distance that can’t be closed in a single quarter.

Question 2: Reorientation After CanG

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

Benedikt: The strongest reorientation wasn’t a single function but a leap in self-definition. Before the market opening, we were the reliable distributor supplying the market with product. With legalization, we understood that distribution is the ticket to entry, not the destination. Distribution scales the market, brands scale the margin. So we built a powerhouse of proprietary brands—AMICI and N!CE—on top of our supply chain, complemented by exclusive partnerships.

The crucial thing is where these brands come from. From thousands of pharmacy relationships, we know firsthand what the market demands—market insight of this depth no one else possesses. That’s exactly where we developed products tailored to the needs of pharmacies and their patients. With our own inventory management system, we also made the pharmacy genuinely capable in medicinal cannabis for the first time. Operational logistics, B2B distribution, and internationalization weren’t competing priorities but parts of the same architecture. We turned a wholesaler into an integrated platform, and it carries most of our value today.

Question 3: Market Entry & Marketplaces

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Benedikt: I don’t believe in a window that closes on a specific date. I believe in entry barriers that rise with market maturity. Anyone entering today must build not a product but a complete, regulatorily licensed infrastructure, plus manufacturer relationships across fifteen countries, a solid quality system, and the trust of thousands of pharmacies. That’s not something you can buy with capital alone—it takes years.

So the market will be decided by 2027 less through new players than through the question of who truly integrates distribution, brands, and systems. Pure marketplaces that only mediate come under pressure because they sit at the thinnest part of the value chain. But whoever controls the entire chain, from import to pharmacy counter, sets the pace. I’m convinced that integrated platforms will shape this market, not storefronts.

Question 4: Regulatory Hurdles

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Benedikt: The biggest brake isn’t a single ban but uncertainty. A market that doesn’t know what rules apply in twelve months invests more cautiously than it should. As a company, we prefer to deliver solutions rather than demands, so I’ll frame it this way: what would help this market most is reliability. Medicinal cannabis should ultimately be treated like any other prescription medication—with clear handling in prescriptions and reliable access through pharmacies.

Where distribution channels operate in gray zones today, we need clean regulatory guardrails, not blanket bans that ultimately hurt patients in underserved regions. If I could wish for one thing in the next twelve months, it’s predictability. Reliability is the most effective growth policy a legislator can pursue in a young market.

Question 5: Full Integration vs. Specialists

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Benedikt: I don’t see the limit where the question suggests. Specialists do excellent work on their portion of the value chain, and we gladly work with many of them. But optimizing a single link in the chain is different from controlling the chain. Our strength is that import, quality testing, logistics, distribution, and our own pharmacy system all converge in one hand. One order, one delivery, one system.

This integration isn’t an end in itself—it’s why supply security is an operational state for us, not a promise. Of course, the model has a price; it demands depth over speed and discipline over rapid scaling. But this depth can’t be replicated by stringing service providers together. The specialist optimizes a piece. We take responsibility for the whole. In a market where patients must be reliably supplied, the whole is the real value.

Question 6: Message at Mary Jane

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

Benedikt: Maybe this, and I say it deliberately on an industry stage. When we started in 2017, cannabis in Germany was a political issue. Today it’s a medical one. That was exactly our goal, and we’re not at the end of that journey yet. In day-to-day business, we talk about delivery quotas, assortment, and margins. What lies beneath, I rarely say openly: we’re building the infrastructure of an entire market right now, and we’re doing it from Hesse for all of Europe.

I believe that in ten years, medicinal cannabis will be prescribed as routinely as any other medication, and that the companies building the invisible infrastructure today will shape this market, not the loudest ones. We don’t want to be the loudest company in the industry. We want to be the company the industry can’t function without.

Question 7: What He’d Do Differently Today

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Benedikt: Honestly, I’d lay the foundation the same way. First the license, then supply capability, then pharmacy trust. That sequence was right, and it’s our advantage today. What I’d do earlier is the step from distribution to brand. In 2017, we first had to prove we could reliably deliver at all—that rightfully consumed all our energy. Today I know the real value lies in the connection between platform and proprietary brands. I’d think about that from day one instead of developing it over years.

And I’d take political engagement seriously earlier. We delivered for a long time and spoke little, because substance had to come first. That was disciplined, but a young market needs a credible voice early on. On the core principle, though—first deliver, then talk—I wouldn’t change a thing.

Question 8: Cansativa in 2030

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Benedikt: A bit of all three, but let me be sharper. By 2030, I see Cansativa as Europe’s leading integrated platform for medicinal cannabis. German market leadership isn’t the goal but the foundation. From there, we carry the model into additional European markets, beginning with the UK, where regulation supports the same integrated model.

Consolidation will be part of this story, because young markets always order themselves, and we want to stand on the shaping side of that order. I understand „pharma player“ as a claim to quality and seriousness, and I share that. But our core remains what it’s always been. We enable a functioning market. Others build a product. We build the infrastructure that market runs on. If we’ve accomplished that in multiple European countries by 2030, we’ll have achieved our real goal.

Note: This interview was conducted in writing. Answers have been lightly edited for readability and grammar without changing content. Benedikt Sons presents a live podcast at the Mary Jane Berlin. This is an editorial interview, not a paid contribution.

Name	Borlabs Cookie
Anbieter	Eigentümer dieser Website, Impressum
Zweck	Speichert die Einstellungen der Besucher, die in der Cookie Box von Borlabs Cookie ausgewählt wurden.
Cookie Name	borlabs-cookie
Cookie Laufzeit	1 Jahr

Akzeptieren	Google Analytics
Name	Google Analytics
Anbieter	Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Zweck	Cookie von Google für Website-Analysen. Erzeugt statistische Daten darüber, wie der Besucher die Website nutzt.
Datenschutzerklärung	https://policies.google.com/privacy?hl=de
Cookie Name	_ga,_gat,_gid
Cookie Laufzeit	2 Jahre

Akzeptieren	Facebook
Name	Facebook
Anbieter	Meta Platforms Ireland Limited, 4 Grand Canal Square, Dublin 2, Ireland
Zweck	Wird verwendet, um Facebook-Inhalte zu entsperren.
Datenschutzerklärung	https://www.facebook.com/privacy/explanation
Host(s)	.facebook.com

Akzeptieren	Soundcloud
Name	Soundcloud
Anbieter	Soundcloud
Zweck	Wird verwendet, um Soundcloud Inhalte zu entsperren.
Datenschutzerklärung	https://soundcloud.com/pages/privacy
Host(s)	soundcloud.com

Akzeptieren	Instagram
Name	Instagram
Anbieter	Meta Platforms Ireland Limited, 4 Grand Canal Square, Dublin 2, Ireland
Zweck	Wird verwendet, um Instagram-Inhalte zu entsperren.
Datenschutzerklärung	https://help.instagram.com/519522125107875/?maybe_redirect_pol=0
Host(s)	.instagram.com
Cookie Name	pigeon_state
Cookie Laufzeit	Sitzung

Cansativa CEO Benedikt Sons: "We Want to Be the Company the Industry Can't Function Without"

Related Posts

Sanity Group und Astrasana: avaay-Medizinalcannabis für den Schweizer Markt

Decode the Bud: Adele Hollmann über das Ganjier-Modell in Deutschland

Folge uns bei:

Beliebte Artikel

Aktuelle News

Produktvorstellungen

Cansativa CEO Benedikt Sons: "We Want to Be the Company the Industry Can't Function Without"

Was dich auch interessieren könnte...

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

Since 2024, Cansativa has been a central player in the legalized market. What market shares are we actually talking about, and how do they compare to the three most important competitors?

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions

What market share does Cansativa have in Germany?

Who is Benedikt Sons?

Is Cansativa expanding beyond Germany?

Where will you meet Benedikt Sons in 2026?

Since 2024, Cansativa has been a central player in the legalized market. What market shares are we actually talking about, and how do they compare to the three most important competitors?

Which strategic reorientation was strongest for Cansativa after the Cannabis Act (CanG) came into force: operational logistics, patient onboarding, B2B distribution, or internationalization?

The medicinal market in Germany is growing rapidly. At what point does the window close for new competitors, and which marketplaces will dominate by 2027?

Which regulatory hurdles most strongly brake the German distribution business in 2026, and which would you most like to see removed in the next 12 months?

Cansativa committed early to full integration. Where do you see the limits of this model today compared to specialized pharmacy service providers?

Mary Jane is an industry stage. What message will you place in your live podcast that you don’t normally speak openly about in day-to-day business?

If you had to launch a cannabis distributor in Germany today: what would you do differently than Cansativa did in 2017?

Where do you see Cansativa in 2030: German market leader, European consolidator, or vertically integrated pharma player?

Frequently Asked Questions